Delcath Systems (NASDAQ:DCTH) Hits New 12-Month High – Here’s What Happened

Delcath Systems, Inc. (NASDAQ:DCTH) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $17.42 and last traded at $17.22, with a volume of 1228262 shares traded. The stock had previously closed at $16.67.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $32 price target while sharply raising its EPS forecasts. The firm now expects a smaller FY2026 loss of $0.17 per share, versus its prior estimate of $0.88, followed by profitability in FY2027 at $0.12 per share. Longer-term estimates were also increased to $0.56 for FY2028, $0.97 for FY2029 and $1.46 for FY2030, suggesting improved confidence in Delcath’s earnings trajectory. MarketBeat analyst estimates
• Positive Sentiment: Zacks highlighted DCTH as a potential momentum stock, citing favorable price momentum and improving earnings-estimate revisions. Another Zacks analysis said Wall Street analysts see potential upside of approximately 42.8%, although price-target projections are not guaranteed. Zacks momentum stock analysis Zacks price target analysis
• Neutral Sentiment: Reported short interest was zero shares both on August 11 and July 27, producing a zero-day short-interest ratio. Because the report also shows an invalid “NaN” change, the data provides no meaningful indication of short-covering or bearish pressure.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of research reports. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price (up from $30.00) on shares of Delcath Systems in a research report on Friday. Weiss Ratings reissued a “sell (d+)” rating on shares of Delcath Systems in a research note on Friday. BTIG Research boosted their price target on shares of Delcath Systems from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Zacks Research raised shares of Delcath Systems from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.17.

Delcath Systems Stock Performance

The firm’s 50 day moving average price is $12.61 and its two-hundred day moving average price is $10.97. The firm has a market cap of $597.53 million, a PE ratio of 1,723.72 and a beta of 0.52.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $29.13 million during the quarter, compared to analysts’ expectations of $26.25 million. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. On average, analysts forecast that Delcath Systems, Inc. will post -0.17 earnings per share for the current year.

Institutional Investors Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC acquired a new position in Delcath Systems in the 3rd quarter valued at about $7,164,000. Marshall Wace LLP acquired a new stake in shares of Delcath Systems during the second quarter worth about $6,572,000. Rosalind Advisors Inc. lifted its position in shares of Delcath Systems by 13.8% during the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after purchasing an additional 400,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock valued at $5,936,000 after purchasing an additional 315,583 shares during the period. Finally, Lane Generational LLC purchased a new position in shares of Delcath Systems in the fourth quarter valued at approximately $1,997,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.